EUVIMEDEUVIMED entdecken
Crossref

Melanocortin 1 receptor variants and their association with phenotypic characteristics and sporadic multiple primary melanomas in a cohort of 402 Spanish subjects

Daniel Vírseda-González iD, Pablo Lázaro-Ochaita, Gloria Ribas Despuig, Jose Antonio Avilés-Izquierdo

Experimental Dermatology · 2023

DOI: 10.1111/exd.14739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Daniel Vírseda-González und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Neoplasms, Multiple Primary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The melanocortin 1 receptor (MC1R) gene is considered to be a major determinant of the risk of melanoma. The role of MC1R polymorphisms as predisposing factors for the development of a second primary melanoma is not well established. The present study analyses the characteristics from subjects with certain MC1R variants without any other genetic predisposition, as well as the risk of second primary melanoma associated with these variants. We performed a prospective longitudinal single‐centre study based on follow‐up information of 402 patients diagnosed with cutaneous melanoma. MC1R gene was sequenced in all subjects. High‐risk variants were defined as those previously associated with melanoma (V60L, V92M, I155T, R160W, R163Q and D294H). 253 (63%) patients had at least one predisposing variant. These individuals had higher proportion of red/blonde hair, multiple primary melanomas and first melanoma diagnosis under the age of 60. Second primary melanomas were detected in 28 (3.8%) subjects. Having more than 25 melanocytic nevi was associated significantly to the development of second primary melanomas. A higher proportion of individuals carrying at least one predisposing MC1R variant develop a second melanoma, although statistical significance was not reached. Therefore, some MC1R polymorphisms might determine clinical and histological differences between patients with cutaneous melanoma and may represent a risk factor for second primary melanoma, although more studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsNeoplasms, Multiple PrimaryHumansReceptor, Melanocortin, Type 1Prospective StudiesPhenotypeRisk FactorsGenetic Predisposition to DiseaseCutaneous Malignant Melanoma

Stichwörter der Autor:innen

melanomamultiple primary melanomaphenotyperiskskin cancer

Substanzen

Receptor, Melanocortin, Type 1

Autor:innen und Institutionen

  • Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Grupo de Investigación en Imagen Médica (GIBI230), Hospital Universitario y Politécnico de La Fe, Valencia, Spain.

ORCID-Profile: Daniel Vírseda-González

Zitieren

APA

Vírseda-González, D., Lázaro-Ochaita, P., Ribas Despuig, G., & Avilés-Izquierdo, J. A. (2023). Melanocortin 1 receptor variants and their association with phenotypic characteristics and sporadic multiple primary melanomas in a cohort of 402 Spanish subjects. Experimental Dermatology. https://doi.org/10.1111/exd.14739

Vancouver

Vírseda-González D, Lázaro-Ochaita P, Ribas Despuig G, Avilés-Izquierdo JA. Melanocortin 1 receptor variants and their association with phenotypic characteristics and sporadic multiple primary melanomas in a cohort of 402 Spanish subjects. Experimental Dermatology. 2023. doi:10.1111/exd.14739

BibTeX
@article{VrsedaGonzlez2023,
  author = {Vírseda-González, Daniel and Lázaro-Ochaita, Pablo and Ribas Despuig, Gloria and Avilés-Izquierdo, Jose Antonio},
  title = {Melanocortin 1 receptor variants and their association with phenotypic characteristics and sporadic multiple primary melanomas in a cohort of 402 Spanish subjects},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14739}
}
Kostenlos starten →